Oppenheimer Holdings, Inc. reissued their hold rating on shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in a report published on Tuesday morning. Oppenheimer Holdings also issued estimates for Acceleron Pharma’s Q1 2018 earnings at ($0.68) EPS, Q2 2018 earnings at ($0.69) EPS, Q3 2018 earnings at ($0.68) EPS and Q4 2018 earnings at ($0.66) EPS.

Several other brokerages also recently issued reports on XLRN. Credit Suisse Group set a $35.00 price objective on shares of Acceleron Pharma and gave the stock a buy rating in a research report on Saturday, August 5th. Piper Jaffray Companies raised their price objective on shares of Acceleron Pharma from $32.00 to $40.00 and gave the stock an overweight rating in a research report on Monday, June 26th. Cann restated a hold rating on shares of Acceleron Pharma in a research report on Tuesday. BidaskClub downgraded shares of Acceleron Pharma from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Finally, CIBC downgraded shares of Acceleron Pharma from an outperform rating to a market perform rating in a research report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $41.21.

Acceleron Pharma (NASDAQ XLRN) opened at 37.94 on Tuesday. The firm has a 50-day moving average price of $34.69 and a 200 day moving average price of $30.40. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $41.69. The firm’s market cap is $1.47 billion.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.12. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The company’s revenue was down 3.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.59) earnings per share. Equities research analysts forecast that Acceleron Pharma will post ($2.70) EPS for the current year.

WARNING: “Acceleron Pharma’s (XLRN) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc.” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/09/acceleron-pharmas-xlrn-hold-rating-reaffirmed-at-oppenheimer-holdings-inc.html.

In other Acceleron Pharma news, SVP Ravindra Kumar sold 937 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $29,984.00. Following the completion of the transaction, the senior vice president now directly owns 96,264 shares in the company, valued at $3,080,448. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin F. Mclaughlin sold 34,400 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $1,100,800.00. Following the transaction, the chief financial officer now owns 80,950 shares of the company’s stock, valued at $2,590,400. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,402 shares of company stock valued at $2,105,416. Company insiders own 3.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System raised its position in Acceleron Pharma by 5.2% during the second quarter. California State Teachers Retirement System now owns 56,795 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 2,826 shares in the last quarter. Platinum Investment Management Ltd. raised its position in Acceleron Pharma by 58.3% during the second quarter. Platinum Investment Management Ltd. now owns 69,000 shares of the biopharmaceutical company’s stock valued at $2,096,000 after purchasing an additional 25,400 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Acceleron Pharma by 15.1% during the second quarter. The Manufacturers Life Insurance Company now owns 25,204 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 3,301 shares in the last quarter. State Street Corp raised its position in Acceleron Pharma by 9.4% during the second quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after purchasing an additional 97,199 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its position in Acceleron Pharma by 61.3% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 30,583 shares of the biopharmaceutical company’s stock valued at $929,000 after purchasing an additional 11,624 shares in the last quarter. Institutional investors and hedge funds own 88.07% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.